Press Releases

 
Press Releases
  Date Title and Summary View
May 31, 2007
CRANBURY, N.J., May 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today the pricing of its initial public offering (IPO) of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Amicus has granted the underwriters a 30-day option to purchase up to an additional...
PDF
Mar 30, 2007
CRANBURY, N.J., Mar 30, 2007 /PRNewswire via COMTEX News Network/ -- CRANBURY, N.J., March 30 /PRNewswire/- Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. All shares in the offeri...
PDF
Mar 21, 2007
CRANBURY, N.J., March 21, 2007 /PRNewswire via COMTEX News Network/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present positive results from its recently completed Phase 1 clinical s...
PDF
Mar 20, 2007
Cranbury, NJ, March 20, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today that it will present the results of preclinical studies of Plicera™ (isofagomine tartrate, AT2101) for Gaucher ...
PDF
Mar 19, 2007
Cranbury, NJ, March 19, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present results from studies of Amigal™ (migalastat hydrochloride, AT1001), Amicus' compound in deve...
PDF
Mar 16, 2007
Cranbury, NJ, March 16, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that enrollment has been completed for all ongoing Phase 2 clinical trials of Amigal™ (migalastat hydrochloride, AT1001). ...
PDF
Mar 5, 2007
Cranbury, NJ, March 5, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced that John F. Crowley has returned to his role as President and Chief Executive Officer of the company. Mr. Crowley r...
PDF
Jan 23, 2007
Cranbury, NJ, January 23, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to support research into a ne...
PDF
Dec 14, 2006
Cranbury, NJ, DECEMBER 14, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has commenced Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, following acceptance of an inve...
PDF
Oct 2, 2006
Cranbury, NJ, October 2, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of James E. Dentzer as Chief Financial Officer (CFO). Mr. Dentzer joins Amicus from Biogen Idec In...
PDF
Page: FirstPrevious ...
32
NextLast